1-3 of 3
Joy Ho, MBBS, FRCPA, FRACP
Close
Sort by
Journal Articles

Safety and Efficacy of CEEP (Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) with or without Rituximab in Elderly Patients (>70) with Diffuse Large B-Cell Lymphoma (DLBL): A Retrospective Single Center Experience

Danny Hsu, MBBS FRACP FRCPA, Ibrahim Tohidi-Esfahani, MBBS, Christina Brown, MBBS PhD FRACP FRCPA, Scott Dunkley, MBBS FRACP FRCPA, Stephen Robert Larsen, MBBS FRACP FRCPA PhD, Phoebe Joy Ho, MBBS FRCPA FRACP DPhil, Harry Iland, MBBS FRACP FRCPA MHGSA, John Gibson, MBBS FRACP FRCPA DPhil, Douglas E. Joshua, MBBS DPhil FRACP FRCPA AM
Journal: Blood
Blood (2011) 118 (21): 4957.
https://doi.org/10.1182/blood.V118.21.4957.4957
Published: 2011
Journal Articles

Characterization of Bortezomib Resistance in Multiple Myeloma Cell Lines

Silvia CW Ling, MBBS, FRCPA, FRACP, Angela M Nikolic, BSc, Ammira Al-Shabeeb, BVM, MSc, PhD, Edwin Lau, BSc, Phoebe Joy Ho, MBBS, FRCPA, FRACP, DPhil, Douglas Joshua, BSc, MBBS(Sydney), DPhil(Oxon), John D Allen, BSc, PhD
Journal: Blood
Blood (2008) 112 (11): 2639.
https://doi.org/10.1182/blood.V112.11.2639.2639
Published: 2008
Journal Articles

XBP-1 Levels Predict Sensitivity of Myelomas to Proteasome Inhibitor Bortezomib.

Silvia C. Ling, MBBS, FRACP, FRCPA, Edwin Lau, BSc, Lye L. Ho, MBBS, FRCPA, FRACP, Joy Ho, MBBS, FRCPA, FRACP, Douglas E. Joshua, MBBS, DPHil(Oxon)FR, John Allen, PhD
Journal: Blood
Blood (2007) 110 (11): 1473.
https://doi.org/10.1182/blood.V110.11.1473.1473
Published: 2007